<DOC>
	<DOCNO>NCT02177357</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , tolerability pramipexole , single-agent therapy combination levodopa , patient Parkinson disease live Hong Kong Taiwan .</brief_summary>
	<brief_title>Pramipexole Untreated Levodopa-treated Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Males female least 30 year age diagnosis symptomatic , idiopathic Parkinson disease , stage 14 Modified Hoehn Yahr Scale Females either surgically sterile least 2 year postmenopausal , use reliable method contraception least 2 month prior study entry Females childbearing potential negative pregnancy test screen visit nursing Patients least 3 4 cardinal sign Parkinson disease ( i.e. , rigidity , bradykinesia , rest tremor , postural instability ) without know Suspected cause Parkinsonism Patients levodopa therapy show good response levodopa stable dosage levodopa least 1 month prior study entry Patients able take oral medication Patients must give voluntary write consent study participation must sign Patient Informed Consent Form screen visit , prior initiation studyrelated procedure Atypical parkinsonian syndrome secondary drug ( e.g. , metoclopramide , flunarizine ) , metabolic disorder ( e.g. , Wilson disease ) , encephalitis , degenerative disease ( e.g. , progressive supranuclear palsy , multiplesystem atrophy ) Dementia could impair compliance medication and/or preclude give informed consent ( i.e. , MiniMental Status Examination score ≤22 ) History psychosis History active epilepsy ( e.g. , occurrence seizure ) within 1 year prior screen Second third degree atrioventricular block sick sinus syndrome , rest heart rate 50 beat per minute , congestive heart failure ( New York Heart Association functional Class III IV ) , myocardial infarction within 6 month randomization , clinically significant heart condition ( e.g. , coronary artery disease ) might negatively affect possibility patient complete study Clinically significant liver disease may prevent patient complete study and/or elevation total bilirubin , alkaline phosphatase , lactate dehydrogenase ( LDH ) , serum glutamate pyruvate transaminase ( SGPT ) , serum glutamate oxaloacetate transaminase ( SGOT ) &gt; 1.5 time upper limit normal value Clinically significant renal disease may prevent patient complete study and/or elevation serum creatinine &gt; 1.5 time upper limit normal value Presence active neoplastic disease Surgery within 6 month baseline/randomization visit , opinion investigator , might negatively impact patient 's participation study , history stereotaxic brain surgery ( e.g. , thalamotomy , pallidotomy , deep brain stimulation reduction parkinsonian symptom ) Supine systolic blood pressure le 100 mm Hg evidence ≥20mm Hg decline systolic blood pressure 2 minute stand , compare previous supine systolic blood pressure obtain 5 minute quiet rest , decline blood pressure upon stand associate symptom ( i.e. , symptomatic orthostatic hypotension ) Use dopamine agonist medication ( e.g. , bromocriptine , pergolide ) 2 month prior study entry ( allow medication : selegiline , anticholinergic , amantadine therapy stable dosage 60 day prior study entry remain stable throughout study ) Use neuroleptic , alphamethyldopa , flunarizine within past 6 month Use follow drug within 3 month study entry : methylphenidate , cinnarizine , reserpine , amphetamine , monoamine oxidaseA inhibitor ( e.g. , pargyline , phenelzine , tranylcypromine ) Use pramipexole within past 3 month history adverse reaction allergy pramipexole Unstable dosage centrally active therapy ( e.g. , hypnotic , antidepressant , anxiolytic ) within past 60 day Electroconvulsive therapy within 90 day baseline/randomization visit Participation investigational drug study receipt investigational drug within 30 day prior baseline/randomization . Investigational drug Parkinson disease must discontinue 90 day prior baseline/randomization . Additionally , patient previously randomize study discontinue study participation reentered study Positive hepatitis B screen ( assessed screen visit )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>